Roivant Sciences Q4 EPS Tops Forecast, $770M Settlement Drives 9.9% Stock Jump
Roivant Sciences posted Q4 adjusted EPS of $0.28 versus a forecasted $0.29 loss, while revenue of $2.52M missed the $3.76M estimate. A $770.2M litigation settlement fueled a 9.9% pre-market stock jump, while a 72.7% ACR20 response in IMVT-1402 rheumatoid arthritis trial and Breakthrough Therapy Designation for brepocitinib enhance the pipeline.
1. Fourth-Quarter Financial Results
Roivant reported adjusted EPS of $0.28 in Q4, compared to a consensus forecast loss of $0.29, while revenue totaled $2.52 million, below the $3.76 million estimate and down 67% year over year.
2. Litigation Settlement and Profitability
A $770.2 million litigation settlement with Moderna contributed significantly to earnings, generating income from continuing operations of $355.7 million and transforming a prior-year loss into a profit, which supported a 9.9% pre-market share increase.
3. Clinical Trial Progress and Pipeline Outlook
The company highlighted Phase 1 IMVT-1402 rheumatoid arthritis data showing a 72.7% ACR20 response rate, and noted FDA Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis, positioning brepocitinib for a dermatomyositis launch by September 2026.
4. Cash Position and Upcoming Catalysts
As of March 31, 2026, Roivant held $4.3 billion in cash, cash equivalents, and marketable securities, which management expects to support operations through profitability; additional clinical data readouts are anticipated in the second half of 2026.